Cyrona Cell uses Wharton’s Jelly mesenchymal cells that have been derived from infant umbilical cords as they can:

As type 2 diabetes is a progressive condition that prevents your cells from efficiently using or, in some circumstances, rejecting the hormones that regulate your body's glucose levels all together, the aim of cell therapy is to preserve remaining beta cell function, reverse resistance to the hormones that regulate your body's glucose levels, repair and regenerate areas of damage, and prevent the death of your beta cells.
Scientifically-Proven Results
|
University/Centre |
Results |
|
|
2014 |
General Hospital of Chinese People’s Armed Police Forces and Harbin Medical University, China |
Significantly decreased glucose levels, improved C-peptide levels and beta cell function as well as decreased inflammation in 12 months. |
|
2014 |
University of Texas, United States |
Significantly decreased fasting plasma glucose and blood glucose levels after meals and increased C-peptide and T cell levels in 6 months. |
|
2015 |
Weifang Medical University, China |
Significantly increased fasting C-peptide and C-peptide levels. Three patients became injection-free while the remaining three required lower doses of diabetes medications in 2 years. |
|
2016 |
Fuzhou General Hospital of Nanjing Command, China |
Significantly lower fasting plasma glucose, blood glucose levels after meals, HbA1c levels, and resistance to diabetes medications as well as significantly increased C-peptide and total C-peptide secretion in 6 months. |
|
2016 |
Affiliated Hospital of Qingdao University, China |
Significantly higher C-peptide levels and beta cell function as well as lower blood glucose and HbA1c levels and fewer diabetic complications in 3 years. |
|
2016 |
Anhui Medical University and Tongji University School of Medicine, China |
Significantly higher and more stable improvements in skin temperature, ankle-brachial pressure index, transcutaneous oxygen tension, and fewer incidents of cramping pain as well as significantly increased formation of new blood vessels and completely or gradually healing ulcers in 3 months. |
|
2017 |
Chinese PLA General Hospital, China |
Decreased dependence on diabetes medications by 50% and significantly improved glucose infusion rate in 6 months. |
Achieving high standards in our work is of paramount importance to us. As such, we only produce and use premium grade passage 1 (P1) and passage 2 (P2) Wharton’s Jelly mesenchymal stem cells in all our therapy programmes. These cellular products have also been thoroughly screened and analyzed in accordance with the requirements of The International Society for Cellular Therapy prior to use.
We also use the latest in cellular research and technologies to tailor our therapy programmes according to the needs of the individual. Furthermore, our microbiology and clinical team as well as our extensively experienced board-certified physicians are geared towards your safety and wellbeing.
All our therapy programmes are conducted using premium grade P1 and P2 Wharton’s Jelly mesenchymal cells and by board-certified experienced specialists. All patients are also provided with pre-transfusion analysis reports of any and all cellular and supplementary products used during treatment.
International patients will be provided with airport transfer services and accommodations as well as in-city transportation to and from every therapy session.
As no two people are alike, our specialists review each patient’s medical reports before developing the best treatment protocol to addresses their unique needs. Therefore, before speaking to one of our Customer Service Representatives, it is best to have the following handy:
Download our eBook and receive our weekly in-depth and exclusive newsletter about Type 2 Diabetes.